Vensana Capital closes $425M Fund III to back breakthrough medical technology companies including neurotech
Summary
Vensana Capital closed $425 million for their Fund III dedicated to breakthrough medical technology companies, with neurotechnology and BCI explicitly included in their investment scope. Vensana led Saluda Medical's $100M financing alongside their Fund III activity. The fund represents one of the largest dedicated medical technology venture funds to close in 2025, with a specific focus on device-based therapies that have demonstrated clinical superiority over standard of care.
Why it matters
A $425M medical technology fund with explicit neurotech scope is the largest dedicated med-device VC raise in the neurotech era. Vensana's track record — leading Saluda Medical's financing after Evoke demonstrated RCT superiority — shows they target late-stage de-risked neuromodulation companies approaching commercial scale. Their Fund III creates a major new capital source for Series C+ neuromodulation and BCI companies.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial